Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial.
Francioso S, Almerighi C, Forte P, Bandiera F, Nosotti L, Lionetti R, Taliani G, Piras MR, Ponti ML, Parruti G, Di Candilo F, Gentile S, Piccolo P, Salso A, Riccobelli F, Renzi S, Longo MA, Montalbano M, Zaru S, Biliotti E, Di Masi F, Santopaolo F, Angelico M. Francioso S, et al. Among authors: almerighi c. Dig Liver Dis. 2014 Feb;46(2):164-9. doi: 10.1016/j.dld.2013.10.002. Epub 2013 Nov 13. Dig Liver Dis. 2014. PMID: 24239044 Clinical Trial.
Leptin attenuates ischemia-reperfusion injury in the rat liver.
Carbone M, Campagnolo L, Angelico M, Tisone G, Almerighi C, Telesca C, Lenci I, Moscatelli I, Massoud R, Baiocchi L. Carbone M, et al. Among authors: almerighi c. Transpl Int. 2012 Dec;25(12):1282-8. doi: 10.1111/j.1432-2277.2012.01555.x. Epub 2012 Sep 13. Transpl Int. 2012. PMID: 22973948 Free article.
TUDCA prevents cholestasis and canalicular damage induced by ischemia-reperfusion injury in the rat, modulating PKCalpha-ezrin pathway.
Baiocchi L, Tisone G, Russo MA, Longhi C, Palmieri G, Volpe A, Almerighi C, Telesca C, Carbone M, Toti L, De Leonardis F, Angelico M. Baiocchi L, et al. Among authors: almerighi c. Transpl Int. 2008 Aug;21(8):792-800. doi: 10.1111/j.1432-2277.2008.00682.x. Epub 2008 Apr 23. Transpl Int. 2008. PMID: 18435680 Free article.
Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms.
Bonaccorso S, Puzella A, Marino V, Pasquini M, Biondi M, Artini M, Almerighi C, Levrero M, Egyed B, Bosmans E, Meltzer HY, Maes M. Bonaccorso S, et al. Among authors: almerighi c. Psychiatry Res. 2001 Dec 15;105(1-2):45-55. doi: 10.1016/s0165-1781(01)00315-8. Psychiatry Res. 2001. PMID: 11740974 Clinical Trial.
Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system.
Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Verkerk R, Meltzer H, Maes M. Bonaccorso S, et al. Among authors: almerighi c. J Clin Psychopharmacol. 2002 Feb;22(1):86-90. doi: 10.1097/00004714-200202000-00014. J Clin Psychopharmacol. 2002. PMID: 11799348 Clinical Trial.
18 results